GlassScriptPhysician profile
Christopher Lynn Clement
NPI 1205212537
$8,212.74
in general payments reported to CMS, 2019-2025
21 companies · $1,676 in 2025
The $1,676 reported for 2025 was more than what 80% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,556 · 2021: $632 · 2022: $321 · 2023: $359 · 2024: $669 · 2025: $1,676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,590 · Food and Beverage: $1,113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,590.24 |
| Food and Beverage | $1,113.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Treace Medical Concepts, INC. | $2,353.91 | 2021-2025 | |
| Stryker Corporation | $1,527.67 | 2019 | |
| Orthofix Medical, INC. | $1,439.41 | 2019 | |
| Organogenesis INC. | $777.96 | 2022-2025 | Puraply, Puraply Wound Matrix, Affinity |
| Paragon 28, INC. | $584.34 | 2019 | |
| Crossroads Extremity Systems, LLC | $581.35 | 2019 | |
| Kerecis Limited | $336.18 | 2019-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Smith+Nephew, INC. | $145.41 | 2022-2023 | Stravix |
| Paratek Pharmaceuticals, INC. | $142.70 | 2023 | Nuzyra |
| Integra Lifesciences Corporation | $53.25 | 2019 | |
| Averitas Pharma INC. | $49.41 | 2024 | Qutenza |
| Abbvie INC. | $39.33 | 2022-2025 | |
| Wright Medical Technology, INC. | $34.95 | 2019 | |
| Fusion Orthopedics USA, LLC | $27.47 | 2024 | |
| Reapplix INC. | $21.94 | 2025 | 3c Patch Kit - Box |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Innovation Technologies INC | $21.00 | 2019 | |
| Mimedx Group, INC. | $19.99 | 2025 | |
| Bard Peripheral Vascular, INC. | $18.43 | 2024 | Arista Ah Flexitip |
| Daiichi Sankyo INC. | $14.49 | 2019 | |
| Polynovo North America LLC | $14.36 | 2024 | Novosorb Btm |
| Reprise Biomedical, INC. | $9.19 | 2025 | Miro3d |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Clement listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.